Core Insights - Conestoga Capital Advisors reported that equity markets reached new all-time highs in Q3 2025, but their Mid Cap Composite underperformed with a return of -3.2% net-of-fees compared to a 2.8% gain for the Russell Midcap Growth Index [1] - The focus on high-quality, profitable companies struggled in a risk-on environment during the quarter [1] Company Overview: IDEXX Laboratories, Inc. - IDEXX Laboratories, Inc. is a leader in diagnostics and information systems for veterinary, food, and water testing applications [3] - The company reported a one-month return of -1.74% and a 52-week gain of 38.06%, with shares closing at $637.13 on October 21, 2025, and a market capitalization of $50.97 billion [2] - IDEXX's revenue increased by 11% as reported and 9% organically in Q2 2025, despite weak veterinarian visits [4] Performance and Market Position - IDEXX Laboratories experienced strong earnings in Q3 2025, with accelerated organic revenue growth and rapid adoption of their latest premium instrument [3] - The number of hedge funds holding IDEXX shares decreased from 51 to 48 from the previous quarter, indicating a slight decline in popularity among institutional investors [4]

Core Insights - Hologic (HOLX) and Idexx Laboratories (IDXX) are both considered by investors interested in Medical - Instruments stocks, with a focus on determining which stock is more attractive to value investors [1] Valuation Metrics - Both HOLX and IDXX currently hold a Zacks Rank of 2 (Buy), indicating positive revisions to their earnings estimates and improving earnings outlooks [3] - HOLX has a forward P/E ratio of 16.05, while IDXX has a significantly higher forward P/E of 51.02 [5] - The PEG ratio for HOLX is 2.47, compared to IDXX's PEG ratio of 4.17, suggesting that HOLX may be undervalued relative to its expected earnings growth [5] - HOLX's P/B ratio is 3.3, while IDXX's P/B ratio is 35.29, further indicating that HOLX is more attractively valued [6] - Based on these valuation metrics, HOLX receives a Value grade of B, whereas IDXX receives a Value grade of D, suggesting that HOLX is the superior value option at this time [6]

Core Insights - IDEXX Laboratories, Inc. (IDXX) is scheduled to release its third-quarter 2025 results on November 3, before the market opens, with expectations of strong performance based on previous quarters [1][9] Revenue and Earnings Estimates - The Zacks Consensus Estimate for revenues is $1.07 billion, reflecting a 9.8% increase from the previous year [2][9] - The Zacks Consensus Estimate for EPS is $3.14, indicating a rise of 12.1% year-over-year [2][9] Performance Drivers - The Companion Animal Group (CAG) is anticipated to significantly contribute to IDEXX's revenue, driven by strong global execution, higher price realization, and increased test volumes [4][9] - The adoption of innovations like the Catalyst Pancreatic Lipase and the IDEXX Cancer Dx diagnostic panel is expected to enhance revenue from CAG Diagnostics [5][9] - Robust placements of premium instruments, particularly the IDEXX inVue Dx Analyzer, are likely to support growth in diagnostic services and accessories [6][9] Segment Performance - CAG business revenues are projected to increase by 10% year-over-year in Q3 2025 [7] - The Water segment is expected to benefit from higher testing volumes in Europe and Asia Pacific, with an estimated 8.6% year-over-year growth [10] - The Livestock, Poultry, and Dairy (LPD) division is forecasted to see a 5% year-over-year increase in revenues, supported by high test volumes and favorable price realization [11] Earnings Expectations - IDEXX Laboratories has an Earnings ESP of +0.23%, indicating a higher likelihood of beating estimates [12] - The company currently holds a Zacks Rank of 2 (Buy), suggesting positive market sentiment [13]

Valued at a market cap of $50.7 billion, IDEXX Laboratories, Inc. (IDXX) is a global leader in veterinary diagnostics and software solutions. Headquartered in Westbrook, Maine, the company develops and distributes products and services for companion animal veterinary, livestock and poultry, dairy, and water testing markets. IDEXX operates through three primary segments: Companion Animal Group (CAG), Water, and Livestock, Poultry, and Dairy (LPD). The veterinary giant is ready to announce its fiscal Q3 ear ...

Core Viewpoint - IDEXX Laboratories, Inc. is set to release its Q3 2025 financial results on November 3, 2025, before market opening, indicating the company's ongoing commitment to transparency and communication with investors [1] Financial Results Announcement - The financial results will be released before the market opens on November 3, 2025 [1] - An analyst conference call is scheduled to begin at 8:30 a.m. ET on the same day [1] - A live webcast of the conference call, along with a transcript of prepared remarks and the Q3 2025 Earnings Snapshot, will be accessible through a link on the IDEXX website [1]

Core Viewpoint - IDEXX Laboratories, Inc. has announced the election of Karen Peacock to its Board of Directors, effective October 6, 2025, highlighting her extensive experience in B2B, SaaS software, and AI [1] Group 1 - Karen Peacock is recognized as a highly accomplished executive, bringing valuable expertise to the IDEXX Board of Directors [1] - The election of Karen Peacock is seen as a strategic move to enhance the company's leadership in pet healthcare innovation [1] - Lawrence D. Kingsley, the Independent Non-Executive Board Chair, expressed strong support for Karen's appointment [1]

Core Insights - IDEXX Laboratories, Inc. (NASDAQ: IDXX) has experienced marginal losses over the past month but has seen significant gains of nearly 50% year-to-date [1] Company Performance - The company is positioned well in the defensible market, contributing to its strong performance this year [1]

Core Insights - IDEXX Laboratories, Inc. is recognized as one of the 12 Best Healthcare Stocks to Buy and Hold for 5 Years, specializing in animal health diagnostics and related services [1] - The company reported Q2 earnings for August 2025, with revenue of $1.11 billion, marking a 10.6% year-over-year increase, and earnings per share of $3.63, exceeding market expectations [2] - The launch of the inVue Dx analyzer has been a significant growth driver, with 2,400 units installed in Q2, leading to an upward revision of the full-year installation target to 5,500 units [3] - IDEXX shares have delivered a 97% return over the past three years, outperforming competitors like Zoetis and the broader market, with projected earnings per share for 2025 between $12.40 and $12.76 [4]

Core Insights - Hologic (HOLX) is currently viewed as a more attractive investment compared to Idexx Laboratories (IDXX) based on valuation metrics and earnings outlook [3][7]. Valuation Metrics - Hologic has a forward P/E ratio of 15.95, significantly lower than Idexx's forward P/E of 50.91 [5]. - The PEG ratio for Hologic is 2.45, while Idexx's PEG ratio stands at 4.16, indicating Hologic may offer better value relative to its expected earnings growth [5]. - Hologic's P/B ratio is 3.1, compared to Idexx's P/B of 35.04, further suggesting Hologic is undervalued [6]. Earnings Outlook - Hologic has a Zacks Rank of 2 (Buy), indicating an improving earnings outlook, while Idexx has a Zacks Rank of 3 (Hold) [3][7]. - The positive revisions to earnings estimates for Hologic enhance its attractiveness for value investors [3]. Value Grades - Hologic holds a Value grade of B, whereas Idexx has a Value grade of D, reflecting Hologic's superior valuation metrics [6].

Core Insights - IDEXX Laboratories (IDXX) has experienced a significant stock price increase of 52.9% year-to-date, outperforming the industry's decline of 12.9% and the S&P 500 Composite's gain of 13.8% [1][8] Company Performance - The company holds a Zacks Rank 3 (Hold) and demonstrates strong strategic execution through new business gains, high customer retention, and solid net price realization [2] - IDEXX's Companion Animal Group (CAG) Diagnostics segment has shown consistent recurring revenue growth above sector levels, driven by increased utilization of existing and new test offerings, customer acquisition, and modest annual price increases [4] Financial Highlights - In Q2 2025, worldwide CAG Diagnostics recurring revenues grew 7.5% organically, supported by a net price improvement of approximately 4% and a 62% increase in instrument revenues [5][8] - Internationally, CAG recurring revenues rose by 11%, aided by software demand and new users [8][9] - The Zacks Consensus Estimate projects IDEXX's earnings per share (EPS) to increase by 17.6% in 2025 and 12.1% in 2026, with revenues expected to grow by 8.6% to $4.23 billion in 2025 [11] Product and Service Innovations - IDEXX's cloud-based products, including ezyVet and Animana, are in high demand, with the newly introduced Vello software solution experiencing double-digit sequential growth in active users [6] - The company is enhancing its customer engagement solutions by integrating the Greenline Pet digital platform, acquired in 2024 [6] Strategic Growth Initiatives - IDEXX is focusing on strategic investments to strengthen future growth prospects, particularly in fast-growing regions, while maintaining strong business performance [9]